Unlike the description by Wult, Norwood and Steinbach groups, who showed that ABCA3 is highly expressed in acute meyloid leukemia samples and is associated with unfavorable clinical treatment outcome [24,33,45], in the present study, lower expression level of ABCA3 was found not only in AML but also in CML groups, especially in CML-CP and CR groups. The gene discussed is ABCA3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.